The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
Diabetes is a common cause of chronic kidney disease (CKD), but in aggregate, non-diabetic diseases account for a higher proportion of cases of CKD than diabetes in many parts of the world. Inhibition of the renin–angiotensin system reduces the risk of kidney disease progression and treatments that...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Published: |
Oxford University Press
2018
|
| _version_ | 1797073445039636480 |
|---|---|
| author | Herrington, W Preiss, D Haynes, R von Eynatten, M Staplin, N Hauske, S George, J Green, J Landray, M Baigent, C Wanner, C |
| author_facet | Herrington, W Preiss, D Haynes, R von Eynatten, M Staplin, N Hauske, S George, J Green, J Landray, M Baigent, C Wanner, C |
| author_sort | Herrington, W |
| collection | OXFORD |
| description | Diabetes is a common cause of chronic kidney disease (CKD), but in aggregate, non-diabetic diseases account for a higher proportion of cases of CKD than diabetes in many parts of the world. Inhibition of the renin–angiotensin system reduces the risk of kidney disease progression and treatments that lower blood pressure (BP) or low-density lipoprotein cholesterol reduce cardiovascular (CV) risk in this population. Nevertheless, despite such interventions, considerable risks for kidney and CV complications remain. Recently, large placebo-controlled outcome trials have shown that sodium-glucose co-transporter-2 (SGLT-2) inhibitors reduce the risk of CV disease (including CV death and hospitalization for heart failure) in people with type 2 diabetes who are at high risk of atherosclerotic disease, and these effects were largely independent of improvements in hyperglycaemia, BP and body weight. In the kidney, increased sodium delivery to the macula densa mediated by SGLT-2 inhibition has the potential to reduce intraglomerular pressure, which may explain why SGLT-2 inhibitors reduce albuminuria and appear to slow kidney function decline in people with diabetes. Importantly, in the trials completed to date, these benefits appeared to be maintained at lower levels of kidney function, despite attenuation of glycosuric effects, and did not appear to be dependent on ambient hyperglycaemia. There is therefore a rationale for studying the cardio-renal effects of SGLT-2 inhibition in people at risk of CV disease and hyperfiltration (i.e. those with substantially reduced nephron mass and/or albuminuria), irrespective of whether they have diabetes. |
| first_indexed | 2024-03-06T23:22:15Z |
| format | Journal article |
| id | oxford-uuid:6921189b-3226-4398-848d-a679f8d6e0da |
| institution | University of Oxford |
| last_indexed | 2024-03-06T23:22:15Z |
| publishDate | 2018 |
| publisher | Oxford University Press |
| record_format | dspace |
| spelling | oxford-uuid:6921189b-3226-4398-848d-a679f8d6e0da2022-03-26T18:49:25ZThe potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY studyJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:6921189b-3226-4398-848d-a679f8d6e0daSymplectic Elements at OxfordOxford University Press2018Herrington, WPreiss, DHaynes, Rvon Eynatten, MStaplin, NHauske, SGeorge, JGreen, JLandray, MBaigent, CWanner, CDiabetes is a common cause of chronic kidney disease (CKD), but in aggregate, non-diabetic diseases account for a higher proportion of cases of CKD than diabetes in many parts of the world. Inhibition of the renin–angiotensin system reduces the risk of kidney disease progression and treatments that lower blood pressure (BP) or low-density lipoprotein cholesterol reduce cardiovascular (CV) risk in this population. Nevertheless, despite such interventions, considerable risks for kidney and CV complications remain. Recently, large placebo-controlled outcome trials have shown that sodium-glucose co-transporter-2 (SGLT-2) inhibitors reduce the risk of CV disease (including CV death and hospitalization for heart failure) in people with type 2 diabetes who are at high risk of atherosclerotic disease, and these effects were largely independent of improvements in hyperglycaemia, BP and body weight. In the kidney, increased sodium delivery to the macula densa mediated by SGLT-2 inhibition has the potential to reduce intraglomerular pressure, which may explain why SGLT-2 inhibitors reduce albuminuria and appear to slow kidney function decline in people with diabetes. Importantly, in the trials completed to date, these benefits appeared to be maintained at lower levels of kidney function, despite attenuation of glycosuric effects, and did not appear to be dependent on ambient hyperglycaemia. There is therefore a rationale for studying the cardio-renal effects of SGLT-2 inhibition in people at risk of CV disease and hyperfiltration (i.e. those with substantially reduced nephron mass and/or albuminuria), irrespective of whether they have diabetes. |
| spellingShingle | Herrington, W Preiss, D Haynes, R von Eynatten, M Staplin, N Hauske, S George, J Green, J Landray, M Baigent, C Wanner, C The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study |
| title | The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study |
| title_full | The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study |
| title_fullStr | The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study |
| title_full_unstemmed | The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study |
| title_short | The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study |
| title_sort | potential for improving cardio renal outcomes by sodium glucose co transporter 2 inhibition in people with chronic kidney disease a rationale for the empa kidney study |
| work_keys_str_mv | AT herringtonw thepotentialforimprovingcardiorenaloutcomesbysodiumglucosecotransporter2inhibitioninpeoplewithchronickidneydiseasearationalefortheempakidneystudy AT preissd thepotentialforimprovingcardiorenaloutcomesbysodiumglucosecotransporter2inhibitioninpeoplewithchronickidneydiseasearationalefortheempakidneystudy AT haynesr thepotentialforimprovingcardiorenaloutcomesbysodiumglucosecotransporter2inhibitioninpeoplewithchronickidneydiseasearationalefortheempakidneystudy AT voneynattenm thepotentialforimprovingcardiorenaloutcomesbysodiumglucosecotransporter2inhibitioninpeoplewithchronickidneydiseasearationalefortheempakidneystudy AT staplinn thepotentialforimprovingcardiorenaloutcomesbysodiumglucosecotransporter2inhibitioninpeoplewithchronickidneydiseasearationalefortheempakidneystudy AT hauskes thepotentialforimprovingcardiorenaloutcomesbysodiumglucosecotransporter2inhibitioninpeoplewithchronickidneydiseasearationalefortheempakidneystudy AT georgej thepotentialforimprovingcardiorenaloutcomesbysodiumglucosecotransporter2inhibitioninpeoplewithchronickidneydiseasearationalefortheempakidneystudy AT greenj thepotentialforimprovingcardiorenaloutcomesbysodiumglucosecotransporter2inhibitioninpeoplewithchronickidneydiseasearationalefortheempakidneystudy AT landraym thepotentialforimprovingcardiorenaloutcomesbysodiumglucosecotransporter2inhibitioninpeoplewithchronickidneydiseasearationalefortheempakidneystudy AT baigentc thepotentialforimprovingcardiorenaloutcomesbysodiumglucosecotransporter2inhibitioninpeoplewithchronickidneydiseasearationalefortheempakidneystudy AT wannerc thepotentialforimprovingcardiorenaloutcomesbysodiumglucosecotransporter2inhibitioninpeoplewithchronickidneydiseasearationalefortheempakidneystudy AT herringtonw potentialforimprovingcardiorenaloutcomesbysodiumglucosecotransporter2inhibitioninpeoplewithchronickidneydiseasearationalefortheempakidneystudy AT preissd potentialforimprovingcardiorenaloutcomesbysodiumglucosecotransporter2inhibitioninpeoplewithchronickidneydiseasearationalefortheempakidneystudy AT haynesr potentialforimprovingcardiorenaloutcomesbysodiumglucosecotransporter2inhibitioninpeoplewithchronickidneydiseasearationalefortheempakidneystudy AT voneynattenm potentialforimprovingcardiorenaloutcomesbysodiumglucosecotransporter2inhibitioninpeoplewithchronickidneydiseasearationalefortheempakidneystudy AT staplinn potentialforimprovingcardiorenaloutcomesbysodiumglucosecotransporter2inhibitioninpeoplewithchronickidneydiseasearationalefortheempakidneystudy AT hauskes potentialforimprovingcardiorenaloutcomesbysodiumglucosecotransporter2inhibitioninpeoplewithchronickidneydiseasearationalefortheempakidneystudy AT georgej potentialforimprovingcardiorenaloutcomesbysodiumglucosecotransporter2inhibitioninpeoplewithchronickidneydiseasearationalefortheempakidneystudy AT greenj potentialforimprovingcardiorenaloutcomesbysodiumglucosecotransporter2inhibitioninpeoplewithchronickidneydiseasearationalefortheempakidneystudy AT landraym potentialforimprovingcardiorenaloutcomesbysodiumglucosecotransporter2inhibitioninpeoplewithchronickidneydiseasearationalefortheempakidneystudy AT baigentc potentialforimprovingcardiorenaloutcomesbysodiumglucosecotransporter2inhibitioninpeoplewithchronickidneydiseasearationalefortheempakidneystudy AT wannerc potentialforimprovingcardiorenaloutcomesbysodiumglucosecotransporter2inhibitioninpeoplewithchronickidneydiseasearationalefortheempakidneystudy |